+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

You are here : Home / 2018 / July (Page 3)

Judith Guasch, (NANBIOSIS Unit 6) has been granted with a Ramon y Cajal grant from the Spanish Goverment

Judith Guasch holds a senior postdoctoral research position at the NANOMOL group CIBER-BBN at  ICMAB-CSIC that coordinates NANBIOSIS Unit 6 Biomaterial Processing and Nanostructuring Unit, after being awarded with a TecnioSpring fellowship  (Marie Curie Fellow, Cofund – Catalan Government and EU). Since 2017 she is also head of a Max Planck Partner Group (Dynamic Biomimetics for Cancer Immunotherapy) in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). Judith’s research interests are focused on the design, synthesis, and fabrication of multifunctional molecular and supramolecular materials for biomedical applications. Special interest is devoted to study the cell-material interaction for improving novel adoptive cell therapies for the treatment of cancer. She studied Chemistry at the UB (2006) and she received her PhD in 2011 from ICMAB. Afterwards, she carried out postdoctoral research at the Max Planck Institute for Intelligent Systems (Stuttgart, Germany).

• Read More

«The combination of nanotechnology with bioengineering and biomedicine allows us to act on the human body on a molecular scale»

Josep Samitier, Scientific Director of NANBIOSIS Unit 7 Nanotechnology Unit, has been highlighted in ‘Dominical’ supplement of the Diari de Girona last week.

More information here 

• Read More

Parasympathetic tone activity evaluation to discriminate ketorolac and ketorolac/tramadol analgesia level in swine

Francisco M. Sánchez-Margallo, Assistant Director of NANBIOSIS and Scientific Director of JUMISC is co-author of the article “Parasympathetic tone activity evaluation to discriminate ketorolac and ketorolac/tramadol analgesia level in swine”, publish by   2018 Jun 14. doi: 10.1213/ANE.0000000000003573. [Epub ahead of print]

Abstract

BACKGROUND:

Evaluation of nociceptive–antinociceptive balance during general anesthesia is still challenging and routinely based on clinical criteria. Analgesic drug delivered may be optimized with parasympathetic tone activity (PTA) monitor. This study compares ketorolac and ketorolac/tramadol balance analgesia using a PTA monitor.

METHODS:

Pain intensity response was assessed using a 0–100 numerical state scale (PTA) after nociceptive stimuli in pigs under stable sevoflurane anesthesia. Bispectral index, heart rate, noninvasive blood pressure, and respiratory parameters were also measured. Animals were divided into 3 groups: without analgesia, ketorolac, and ketorolac/tramadol. Mean values or mean areas under the curve (AUC) in selected time periods were compared over time and between groups through a mixed-model repeated measures analysis of variance and nonparametric Kruskal-Wallis tests, followed by Bonferroni or Dunn’s multiple comparisons.

RESULTS:

It was observed a significant decrease in the PTA AUC mean value after application of the stimulus in animals treated without analgesia and only with ketorolac. The PTA AUC mean value in the control group was significantly lower than the corresponding mean in ketorolac group. The ketorolac/tramadol group showed the highest PTA AUC mean values, significantly different from those obtained for the other 2 groups, with no significant differences detected over time. Bispectral index means showed no statistically significant differences either over time periods or between different treatment groups. Heart rate showed only a statistically significant increase in AUC mean between without analgesia and ketorolac/tramadol group, in the time period after the stimulus application. Noninvasive blood pressure means showed no statistically significant differences over time and between treatment groups.

CONCLUSIONS:

This study shows that a low dose combination of ketorolac and tramadol is sufficient to block the pain responses induced with a needle holder in pigs 20 minutes after its administration. The PTA monitor was able to clearly recognize the analgesic level between treatments and may be used to optimize analgesic drug delivered

• Read More

Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin

Researchers of NANBIOSIS Unit 1 and NANBIOSIS Unit 18, led by Prof Antoni Villaverde have published the article “Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin” at SMALL journal.

Under the unmet need of efficient tumor‐targeting drugs for oncology, a recombinant version of the plant toxin ricin (the modular protein T22‐mRTA‐H6) is engineered to self‐assemble as protein‐only, CXCR4‐targeted nanoparticles. The soluble version of the construct self‐organizes as regular 11 nm planar entities that are highly cytotoxic in cultured CXCR4+ cancer cells upon short time exposure, with a determined IC50 in the nanomolar order of magnitude. The chemical inhibition of CXCR4 binding sites in exposed cells results in a dramatic reduction of the cytotoxic potency, proving the receptor‐dependent mechanism of cytotoxicity. The insoluble version of T22‐mRTA‐H6 is, contrarily, moderately active, indicating that free, nanostructured protein is the optimal drug form. In animal models of acute myeloid leukemia, T22‐mRTA‐H6 nanoparticles show an impressive and highly selective therapeutic effect, dramatically reducing the leukemia cells affectation of clinically relevant organs. Functionalized T22‐mRTA‐H6 nanoparticles are then promising prototypes of chemically homogeneous, highly potent antitumor nanostructured toxins for precise oncotherapies based on self‐mediated intracellular drug delivery.

See article: https://doi.org/10.1002/smll.201800665

• Read More

Prof. Laura Lehuga, new Associate Editor at Analyst Editorial Board

Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit, at Catalan Institute of Nanoscience and Nanotechnology,  has joined the Analyst Editorial Board as an Associate Editor from today.

Analyst publishes analytical and bioanalytical research that reports premier fundamental discoveries and inventions and the applications of those discoveries, unconfined by traditional discipline barriers

Laura Lechuga is the CSIC Research Professor at the Catalan Institute of Nanoscience and Nanotechnology, Spain. She is the leader of the CIBER-BBN-ICN2 Nanobiosensors and Bioanalytical Applications Group, which focusses on the technological development of nanophotonic biosensors, their integration into portable lab-on-a-chip platforms and their application in clinical and environmental diagnostics. Professor Lechuga gained her PhD in chemistry in 1992 from the Universidad Complutense de Madrid. Between 2012 and 2015 she was an adjunct professor at the University of Norway within their department of Physics and Technology at the Artic. She has also been a distinguished visiting professor at the School of Electrical and Computer Sciences of the Universidade Estadual de Campinas (Brazil) since 2013.

• Read More